Raze Therapeutics Appoints Mark Manfredi as Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Raze Therapeutics, a leading next-generation cancer metabolism company, announced today the appointment of Mark Manfredi, Ph.D., as Chief Scientific Officer. Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology, having served most recently as Vice President, Oncology Biology at Takeda Pharmaceuticals.

"Raze's pursuit of a new class of therapeutics targeting one-carbon metabolism represents a groundbreaking and potentially revolutionary approach to the treatment of solid and hematologic cancers"
"Raze is translating breakthrough insights in one-carbon metabolism into novel therapeutic programs for patients with solid and hematologic cancers," said Jason Rhodes, acting Chief Executive Officer of Raze. "Mark brings proven scientific acumen and strong leadership skills to this important mission, and we are delighted to have him join the Raze team in this critical role."

As Vice President, Oncology Biology at Takeda, Dr. Manfredi was a member of the organization's senior R&D management team responsible for the global oncology R&D strategy. He led Takeda's Oncology Biology group, which included functions spanning target identification to preclinical translational support for development projects. Prior to that, Dr. Manfredi served as Senior Director at Takeda, leading departments responsible for the scientific strategy for late preclinical and early development projects. Dr. Manfredi received his B.S. from the University of Rhode Island and earned his Ph.D. in biology from Boston College.

"Raze's pursuit of a new class of therapeutics targeting one-carbon metabolism represents a groundbreaking and potentially revolutionary approach to the treatment of solid and hematologic cancers," said Dr. Manfredi. "I look forward to joining the impressive team at Raze as we progress 1C targets toward the clinic and continue to build the strategy to realize the therapeutic potential of this promising pathway."

About One-Carbon (1C) Metabolism

Targeting cellular metabolism is an increasingly important therapeutic approach for the treatment of people with cancer. In many types of cancer, the normal function of one-carbon (1C) metabolism is misregulated, driving tumor growth, proliferation and survival, primarily by supporting biomass accumulation. Breakthrough insights by Raze's founders have identified 1C metabolic targets specific to certain tumors that, when selectively inhibited, stop the ability of tumors to accumulate biomass, offering the promise of targeted new cancer therapeutics.

About Raze Therapeutics

Raze Therapeutics is dedicated to the discovery and development of the next generation of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, Raze is developing a pipeline of 1C metabolism therapeutics for a range of solid and hematologic cancers, including genetically defined cancers. Raze is led by an experienced management team with a proven track record for building successful biotech companies and recognized scientific leaders in metabolism and cancer biology. The company is funded by leading financial and corporate investors, including Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis. For more information please visit the company's website at: www.razetx.com or follow on Twitter at @RazeTx.


Feinstein Kean Healthcare
Greg Kelley, 617-461-4023
[email protected]

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.